Stanford University School of Medicine’s Lloyd Minor, MD, center, spoke about health care in the era of precision medicine during his recent Flexner Discovery Lecture.

An international team involving Vanderbilt researchers has discovered that a new “checkpoint” protein on immune system cells is active in tumors, and that blocking it — in combination with other treatments — is a successful therapeutic approach in mouse models of cancer.

Vanderbilt University Medical Center’s David Zealear, PhD, has received a $3.6 million grant from the National Institutes of Health (NIH) for a clinical trial to study the effectiveness of bilateral laryngeal pacing in treating patients with a bilaterally paralyzed larynx.

Lloyd Minor, MD, the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, will discuss “Digitally Driven: Health Care in the Era of Precision Health,” during a Flexner Discovery Lecture on Thusday, Feb. 21.

Older patients with a diagnosis of chronic sinusitis — a disease of the nasal cavity and paranasal sinuses that often persists over many years — have a unique inflammatory signature that may render them less responsive to steroid treatment, according to a new study published by Vanderbilt researchers.

Sarah Rohde long had an interest in treating cancer, and her research during her undergraduate and medical school years at the University of Virginia underscored that. What she didn’t expect was to become a surgeon.

Beginning Nov. 6, Vanderbilt’s Department of Otolaryngology will host a monthly support group for patients living with Ménière’s disease, a disorder effecting the inner ear that is characterized by episodes of symptoms such as vertigo (dizziness), tinnitus (a ringing inside the ear) and hearing loss.